Scott T. Tagawa
A5007663088- Prostate Cancer Treatment and Research
- Radiopharmaceutical Chemistry and Applications
- Bladder and Urothelial Cancer Treatments
- Cancer Immunotherapy and Biomarkers
- Cancer Genomics and Diagnostics
- Prostate Cancer Diagnosis and Treatment
- Urinary and Genital Oncology Studies
- Cancer, Lipids, and Metabolism
- PARP inhibition in cancer therapy
- Medical Imaging Techniques and Applications
- Renal cell carcinoma treatment
- Mass Spectrometry Techniques and Applications
- Cancer Treatment and Pharmacology
- Venous Thromboembolism Diagnosis and Management
- Peptidase Inhibition and Analysis
- Cancer Cells and Metastasis
- Hormonal and reproductive studies
- Ubiquitin and proteasome pathways
- Pain Management and Opioid Use
- Epigenetics and DNA Methylation
- Cancer, Hypoxia, and Metabolism
- Urological Disorders and Treatments
- Immunotherapy and Immune Responses
- Genetic factors in colorectal cancer
- Cardiac, Anesthesia and Surgical Outcomes
Cornell University
2016-2025
Weill Cornell Medicine
2016-2025
NewYork–Presbyterian Hospital
2016-2025
Presbyterian Hospital
2016-2025
New York Hospital Queens
2016-2025
Lander Institute
2016-2024
University of California, San Diego
2024
Memorial Sloan Kettering Cancer Center
2013-2024
Mayo Clinic in Arizona
2024
Dana-Farber Cancer Institute
2024
Metastatic castration-resistant prostate cancer remains fatal despite recent advances. Prostate-specific membrane antigen (PSMA) is highly expressed in metastatic cancer. Lutetium-177 (177Lu)–PSMA-617 a radioligand therapy that delivers beta-particle radiation to PSMA-expressing cells and the surrounding microenvironment.
Alterations in the gene encoding fibroblast growth factor receptor (FGFR) are common urothelial carcinoma and may be associated with lower sensitivity to immune interventions. Erdafitinib, a tyrosine kinase inhibitor of FGFR1–4, has shown antitumor activity preclinical models phase 1 study involving patients FGFR alterations.
Neuroendocrine prostate cancer (NEPC) is an aggressive subtype of that most commonly evolves from preexisting adenocarcinoma (PCA). Using Next Generation RNA-sequencing and oligonucleotide arrays, we profiled 7 NEPC, 30 PCA, 5 benign tissue (BEN), validated findings on tumors a large cohort patients (37 169 22 BEN) using IHC FISH. We discovered significant overexpression gene amplification AURKA MYCN in 40% NEPC 5% respectively, evidence they cooperate to induce neuroendocrine phenotype...
Prostate cancer progression requires active androgen receptor (AR) signaling which occurs following translocation of AR from the cytoplasm to nucleus. Chemotherapy with taxanes improves survival in patients castrate resistant prostate (CRPC). Taxanes induce microtubule stabilization, mitotic arrest, and apoptotic cell death, but recent data suggest that can also affect signaling. Here, we report inhibit ligand-induced nuclear downstream transcriptional activation target genes such as...
Abstract Purpose: To assess the efficacy of a single infusion radiolabeled anti-prostate-specific membrane antigen (PSMA) monoclonal antibody J591 (lutetium-177; 177Lu) by prostate-specific (PSA) decline, measurable disease response, and survival. Experimental Design: In this dual-center phase II study, two cohorts with progressive metastatic castration-resistant prostate cancer received one dose 177Lu-J591 (15 patients at 65 mCi/m2, 17 70 mCi/m2) radionuclide imaging. Expansion cohort (n =...
Patients with metastatic urothelial carcinoma (mUC) who progress on platinum-based combination chemotherapy (PLT) and checkpoint inhibitors (CPIs) have limited options that offer objective response rates (ORRs) of approximately 10% a median overall survival (OS) 7-8 months. Sacituzumab govitecan (SG) is TROP-2-directed antibody-drug conjugate an SN-38 payload has shown preliminary activity in mUC.
Geometrically enhanced differential immunocapture (GEDI) and an antibody for prostate-specific membrane antigen (PSMA) are used high-efficiency high-purity capture of prostate circulating tumor cells from peripheral whole blood samples castrate-resistant cancer patients.
Androgen receptor splice variant 7 (AR-V7) results in a truncated receptor, which leads to ligand-independent constitutive activation that is not inhibited by anti-androgen therapies, including abiraterone or enzalutamide. Given previous reports suggested circulating tumor cell (CTC) AR-V7 detection poor prognostic indicator for the clinical efficacy of secondary hormone we conducted prospective multicenter validation study.PROPHECY ( ClinicalTrials.gov identifier: NCT02269982) multicenter,...
Abstract A major hurdle in the study of rare tumors is a lack existing preclinical models. Neuroendocrine prostate cancer an uncommon and aggressive histologic variant that may arise de novo or as mechanism treatment resistance patients with pre-existing castration-resistant cancer. There are few available models to neuroendocrine Here, we report generation characterization tumor organoids derived from needle biopsies metastatic lesions four patients. We demonstrate genomic, transcriptomic,...
<h3>Importance</h3> Understanding molecular mechanisms of response and resistance to anticancer therapies requires prospective patient follow-up clinical functional validation both common low-frequency mutations. We describe a whole-exome sequencing (WES) precision medicine trial focused on patients with advanced cancer. <h3>Objective</h3> To understand how WES data affect therapeutic decision making in cancer identify novel biomarkers response. <h3>Design, Setting, Patients</h3> Patients...
Neuroendocrine prostate cancer (NEPC), also referred to as anaplastic cancer, is a lethal tumor that most commonly arises in late stages of adenocarcinoma (PCA) with predilection metastasize visceral organs. In the current study, we explore for evidence Aurora kinase A (AURKA) and N-myc (MYCN) gene abnormalities are harbingers treatment-related NEPC (t-NEPC). We studied primary tissue from 15 hormone naïve PCAs, 51 castration-resistant cancers, metastatic tumors 72 patients at different...
Abstract Purpose: Neuroendocrine prostate cancer (NEPC) is an aggressive variant of that may develop de novo or as a mechanism treatment resistance. N-myc capable driving NEPC progression. Alisertib inhibits the interaction between and its stabilizing factor Aurora-A, inhibiting signaling, suppressing tumor growth. Patients Methods: Sixty men were treated with alisertib 50 mg twice daily for 7 days every 21 days. Eligibility included metastatic at least one: small-cell neuroendocrine...
PURPOSE In prostate cancer, inactivating CDK12 mutations lead to gene fusion–induced neoantigens and possibly sensitivity immunotherapy. We aimed clinically, pathologically, molecularly characterize CDK12-aberrant cancers. METHODS conducted a retrospective multicenter study identify patients with advanced cancer who harbored somatic loss-of-function mutations. used descriptive statistics their clinical features therapeutic outcomes (prostate-specific antigen [PSA] responses, progression-free...
Standard imaging for assessing osseous metastases in advanced prostate cancer remains focused on altered bone metabolism and is inadequate diagnostic, prognostic, or predictive purposes. We performed a first-in-human phase I/II study of (89)Zr-DFO-huJ591 ((89)Zr-J591) PET/CT immunoscintigraphy to assess performance characteristics detecting compared with conventional modalities (CIM) pathology.Fifty patients progressive metastatic castration-resistant cancers were injected 5 mCi (89)Zr-J591....
In April 2017, the American Urological Association, Society for Radiation Oncology, and of Urologic Oncology released a joint evidence-based practice guideline on clinically localized prostate cancer. The Clinical (ASCO) has policy set procedures endorsing clinical guidelines that have been developed by other professional organizations.The Clinically Localized Prostate Cancer was reviewed developmental rigor methodologists. An ASCO Expert Panel then content recommendations.The determined...
Upper tract urothelial carcinoma (UTUC) is characterized by a distinctly aggressive clinical phenotype. To define the biological features driving this phenotype, we performed an integrated analysis of whole-exome and RNA sequencing UTUC. Here report several key insights from our molecular dissection disease: 1) Most UTUCs are luminal-papillary; 2) UTUC has T-cell depleted immune contexture; 3) High FGFR3 expression enriched in correlates with its microenvironment; 4) Sporadic lower total...
Loss of androgen receptor (AR) signaling dependence occurs in approximately 15%–20% advanced treatment-resistant prostate cancers, and this may manifest clinically as transformation from a adenocarcinoma histology to castration-resistant neuroendocrine cancer (CRPC-NE). The diagnosis CRPC-NE currently relies on metastatic tumor biopsy, which is invasive for patients sometimes challenging diagnose due morphologic heterogeneity. By studying whole-exome sequencing whole-genome bisulfite cell...